Respiratory Devices Market Size, Share, Growth, and Industry Analysis, By Type (Respiratory Positive Airway Pressure Devices,Respiratory Mask,Respiratory Ventilators,Respiratory Oxygen Concentrators,Respiratory Inhalers,Respiratory Resuscitators,Respiratory Nebulizers,Respiratory Humidifiers,Respiratory Oxygen Hoods), By Application (Hospitals,Home Care,Other End-Users), Regional Insights and Forecast to 2035

Respiratory Devices Market Overview

The global Respiratory Devices Market size is projected to grow from USD 32210.54 million in 2026 to USD 34236.59 million in 2027, reaching USD 55759.64 million by 2035, expanding at a CAGR of 6.29% during the forecast period.

The Respiratory Devices Market is a rapidly expanding healthcare sector driven by the growing prevalence of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, sleep apnea, and acute respiratory distress syndrome. According to the World Health Organization (WHO), over 262 million individuals were affected by asthma globally in 2022, while COPD was responsible for more than 3.2 million deaths in the same year.

The United States respiratory devices market remains one of the most dominant globally due to a combination of advanced healthcare infrastructure, high disease prevalence, and a strong network of manufacturers. The Centers for Disease Control and Prevention (CDC) reported that around 16 million Americans are currently diagnosed with COPD, while millions more may remain undiagnosed. In addition, over 25 million Americans suffer from asthma, representing 7.7% of the total U.S. population.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 62% of global respiratory device demand arises from growing chronic conditions, especially asthma, COPD, and sleep-disordered breathing worldwide.
• Major Market Restraint: 48% of limitations stem from expensive advanced respiratory devices, high maintenance costs, and affordability issues in low- and middle-income economies globally.
• Emerging Trends: 55% of growth is influenced by portable respiratory devices, home healthcare demand, and digital integration features like Bluetooth and AI monitoring systems.
• Regional Leadership: 41% of demand originates from North America, while Asia-Pacific contributes 29%, and Europe accounts for 27% global respiratory devices share.
• Competitive Landscape: 46% of respiratory devices market share remains concentrated among top five multinational manufacturers with extensive portfolios, innovation pipelines, and global distribution networks.
• Market Segmentation: 37% of demand originates from hospitals, 33% from home care, and 30% from other healthcare facilities including clinics and emergency services.
• Recent Development: 52% of product launches from 2023 to 2025 emphasized compact designs, sustainability, AI-enabled respiratory devices, and remote digital monitoring solutions.

Respiratory Devices Market Latest Trends

Recent years have witnessed remarkable trends in the Respiratory Devices Market. One of the most significant shifts is the adoption of portable and wearable respiratory devices. Over 34% of patients with chronic respiratory issues now prefer lightweight and mobile devices for daily use, highlighting a shift toward patient convenience and compliance.

Digital integration is another trend, with more than 28% of newly launched devices in 2023 featuring Bluetooth connectivity, remote monitoring capabilities, or integration with mobile applications. This enables real-time monitoring of oxygen levels, airflow, and therapy compliance.

Respiratory Devices Market Dynamics

DRIVER

"Rising prevalence of respiratory diseases"

The global increase in chronic and infectious respiratory illnesses has created an unprecedented demand for respiratory devices. For example, the WHO reported that 3.23 million deaths were linked to COPD in 2019, while lung cancer remains the second most common cancer with over 2.2 million cases worldwide annually. Sleep-disordered breathing impacts nearly 1 billion people globally, fueling demand for sleep apnea-related devices.

RESTRAINT

"High cost of advanced respiratory devices"

Despite technological advances, the high costs of modern respiratory devices remain a significant barrier. For example, non-invasive ventilators can cost more than $5,000 per unit, while advanced portable oxygen concentrators often exceed $3,000. In low- and middle-income countries, where 80% of global COPD-related deaths occur, such costs restrict accessibility. Furthermore, high maintenance and replacement expenses deter healthcare facilities from large-scale adoption.

OPPORTUNITY

"Rising demand for home healthcare solutions"

The increasing preference for home healthcare presents major growth opportunities. With 70% of elderly patients preferring home-based treatments and hospital overcrowding becoming more frequent, home respiratory devices are in higher demand. For instance, 45% of oxygen concentrator sales in 2023 were attributed to home use. Portable CPAP machines have grown in popularity among sleep apnea patients, offering a convenient solution for therapy adherence.

CHALLENGE

"Limited healthcare access in emerging regions"

Access to advanced respiratory devices remains a challenge in developing nations, where 90% of asthma-related deaths occur. Limited availability of healthcare infrastructure, particularly in rural areas, exacerbates this issue. For instance, in Sub-Saharan Africa, the physician-to-patient ratio is only 0.2 per 1,000, far below the global average of 1.6. Furthermore, unreliable electricity in certain regions impacts the consistent use of oxygen concentrators and ventilators.

Respiratory Devices Market Segmentation

The Respiratory Devices Market segmentation highlights diverse demand by type and application, covering hospitals, home care, and emergency services, while device categories include ventilators, inhalers, nebulizers, oxygen concentrators, CPAP devices, humidifiers, masks, resuscitators, and oxygen hoods.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Respiratory Positive Airway Pressure Devices: Accounting for 24% demand, PAP devices treat sleep apnea, impacting over 30 million patients in the U.S. Their portability, advanced pressure control, and rising usage in Europe and Asia-Pacific underscore their critical importance.

Respiratory Positive Airway Pressure Devices market is USD 4,080.60 million in 2025, 13.47% share, reaching USD 7,108.45 million by 2034 at 6.28% CAGR globally.

Top 5 Major Dominant Countries in the Respiratory Positive Airway Pressure Devices Segment

• United States: USD 1,630.20 million in 2025, 40.0% share, projected to USD 2,840.95 million by 2034 at 6.25% CAGR within the forecast period.
• Germany: USD 510.80 million in 2025, 12.5% share, expected USD 890.34 million by 2034, expanding strongly at a CAGR of 6.30% across forecast years.
• China: USD 408.06 million in 2025, 10.0% share, anticipated USD 710.84 million by 2034, progressing steadily at 6.29% CAGR in respiratory devices adoption.
• Japan: USD 367.25 million in 2025, 9.0% share, forecasted USD 639.76 million by 2034, sustaining consistent growth at a 6.29% CAGR throughout forecast horizon.
• India: USD 285.64 million in 2025, 7.0% share, projected USD 497.65 million by 2034, demonstrating rising penetration supported by a 6.30% CAGR trend.

Respiratory Mask: Representing 18% share, masks exceeded 250 million units sold globally in 2023. Widely used across hospitals and home care, they provide infection protection, effective oxygen delivery, and patient comfort, driving increased adoption worldwide.

Respiratory Mask market is USD 3,030.44 million in 2025, 10.00% share, expanding to USD 5,245.99 million by 2034, with steady CAGR growth of 6.29% across forecast years.

Top 5 Major Dominant Countries in the Respiratory Mask Segment

• United States: USD 1,060.65 million in 2025, 35.0% share, reaching USD 1,835.09 million by 2034, consistently growing at a 6.28% CAGR.
• Germany: USD 424.26 million in 2025, 14.0% share, expanding to USD 734.44 million by 2034, with adoption advancing steadily at 6.29% CAGR.
• China: USD 333.35 million in 2025, 11.0% share, estimated to USD 576.06 million by 2034, sustaining a CAGR growth rate of 6.30%.
• Japan: USD 272.74 million in 2025, 9.0% share, projected to USD 471.06 million by 2034, reflecting consistent CAGR growth of 6.29%.
• India: USD 212.13 million in 2025, 7.0% share, reaching USD 366.17 million by 2034, progressing firmly at 6.30% CAGR across forecast years.

Respiratory Ventilators: Contributing 20% market share, ventilators are indispensable in intensive care. Global output rose from 77,000 annually to 300,000 units during COVID-19. They remain vital for supporting severe COPD, pneumonia, and respiratory failure patients worldwide.

Respiratory Ventilators market stands at USD 3,939.57 million in 2025, accounting for 13.00% share, and is expected to reach USD 6,819.79 million by 2034 at 6.29% CAGR.

Top 5 Major Dominant Countries in the Respiratory Ventilators Segment

• United States: Market size USD 1,379.85 million in 2025 with 35.0% share, forecasted USD 2,389.92 million by 2034, advancing at a stable CAGR of 6.28%.
• Germany: Estimated USD 472.74 million in 2025, 12.0% share, reaching USD 818.37 million by 2034, showing reliable expansion across the forecast period with a CAGR of 6.29%.
• China: USD 393.96 million in 2025, 10.0% share, projected USD 681.98 million by 2034, progressing steadily throughout the period supported by CAGR growth of 6.30%.
• Japan: Valued USD 315.16 million in 2025, 8.0% share, expected USD 545.58 million by 2034, reflecting consistent adoption trends with CAGR maintained at 6.29%.
• India: USD 236.37 million in 2025, 6.0% share, forecasted USD 409.19 million by 2034, continuing to strengthen adoption with reliable CAGR expansion of 6.30%.

Respiratory Oxygen Concentrators: Capturing 16% share, oxygen concentrators serve over 50% of home-based COPD patients. In 2023, portable models dominated sales, reflecting global preference for long-term, accessible, and reliable oxygen therapy outside hospital settings.

Respiratory Oxygen Concentrators market size is USD 2,878.92 million in 2025, accounting for 9.50% share, expected to reach USD 4,987.69 million by 2034 with CAGR of 6.29%.

Top 5 Major Dominant Countries in the Respiratory Oxygen Concentrators Segment

• United States: USD 1,007.62 million in 2025 with 35.0% share, projected USD 1,744.69 million by 2034, steadily growing under a consistent CAGR rate of 6.28%.
• Germany: Market estimated at USD 345.47 million in 2025, 12.0% share, forecasted USD 597.53 million by 2034, reflecting stable CAGR expansion rate of 6.29%.
• China: Valued USD 287.89 million in 2025, 10.0% share, expected USD 497.77 million by 2034, sustaining progressive CAGR growth trend at 6.30%.
• Japan: USD 230.31 million in 2025, 8.0% share, projected USD 398.92 million by 2034, highlighting consistent long-term adoption with 6.29% CAGR expansion.
• India: USD 172.73 million in 2025, 6.0% share, reaching USD 298.77 million by 2034, rising firmly with dependable CAGR growth rate of 6.30%.

Respiratory Inhalers: With 30% utilization, inhalers support more than 60% of asthma patients globally. Dry powder inhalers are gaining adoption in Asia-Pacific, complementing widespread reliance on metered-dose inhalers in North America and Europe.

Respiratory Inhalers market is valued USD 4,545.66 million in 2025, comprising 15.00% share, and anticipated to expand to USD 7,868.99 million by 2034, with a CAGR of 6.29%.

Top 5 Major Dominant Countries in the Respiratory Inhalers Segment

• United States: Market size USD 1,590.98 million in 2025, 35.0% share, reaching USD 2,754.15 million by 2034, consistently maintaining steady CAGR expansion of 6.28%.
• Germany: Estimated USD 590.94 million in 2025, 13.0% share, projected USD 1,022.67 million by 2034, advancing steadily with robust CAGR trajectory of 6.29%.
• China: Valued USD 454.57 million in 2025, 10.0% share, forecasted USD 786.90 million by 2034, sustaining growth supported by CAGR expansion of 6.30%.
• Japan: USD 363.65 million in 2025, 8.0% share, expected USD 629.52 million by 2034, progressing at a consistent CAGR maintained at 6.29%.
• India: USD 272.74 million in 2025, 6.0% share, forecasted USD 471.14 million by 2034, steadily strengthening presence at a CAGR of 6.30%.

Respiratory Resuscitators: Resuscitators account for 6% of demand, with 15 million annual uses in emergencies worldwide. Disposable versions are rising in popularity, minimizing cross-infection risks and improving safety in critical and pre-hospital settings.

Respiratory Resuscitators market is USD 1,212.18 million in 2025, representing 4.00% share, projected to reach USD 2,099.16 million by 2034, advancing steadily with an expected CAGR of 6.29%.

Top 5 Major Dominant Countries in the Respiratory Resuscitators Segment

• United States: USD 424.26 million in 2025, 35.0% share, projected USD 734.70 million by 2034, sustaining market strength at a consistent CAGR rate of 6.28%.
• Germany: Valued USD 157.58 million in 2025, 13.0% share, expected USD 272.89 million by 2034, expanding at a reliable CAGR pace of 6.29%.
• China: USD 121.22 million in 2025, 10.0% share, forecasted USD 209.92 million by 2034, maintaining stable CAGR trajectory of 6.30%.
• Japan: Estimated USD 96.97 million in 2025, 8.0% share, reaching USD 167.94 million by 2034, sustaining consistent CAGR level of 6.29%.
• India: USD 72.73 million in 2025, 6.0% share, projected USD 125.95 million by 2034, experiencing dependable growth trend with CAGR expansion of 6.30%.

Respiratory Nebulizers: At 12% share, nebulizers support pediatric and elderly patients. In India, six million children annually rely on nebulizers, while global adoption increases due to asthma, bronchitis, and chronic respiratory conditions prevalence.

Respiratory Nebulizers market size is USD 1,818.27 million in 2025, holding 6.00% share, expected to expand to USD 3,148.75 million by 2034 at a CAGR of 6.29%.

Top 5 Major Dominant Countries in the Respiratory Nebulizers Segment

• United States: USD 636.39 million in 2025, 35.0% share, projected USD 1,101.06 million by 2034, sustaining steady CAGR growth throughout forecast period at 6.28%.
• Germany: Valued USD 218.19 million in 2025, 12.0% share, reaching USD 377.85 million by 2034, expanding reliably at CAGR of 6.29% within the global respiratory device market.
• China: USD 181.83 million in 2025, 10.0% share, forecasted USD 314.88 million by 2034, progressing steadily at a CAGR pace of 6.30%.
• Japan: Estimated USD 145.46 million in 2025, 8.0% share, reaching USD 251.90 million by 2034, sustaining CAGR trajectory of 6.29%.
• India: USD 109.10 million in 2025, 6.0% share, projected USD 188.92 million by 2034, advancing steadily with dependable CAGR growth of 6.30%.

Respiratory Humidifiers: Humidifiers hold 7% share, providing airway moisture during oxygen therapy. More than one million units sold in 2023 highlight their role in intensive care and long-term home respiratory treatment globally.

Respiratory Humidifiers market size is USD 909.13 million in 2025, accounting for 3.00% share, anticipated to reach USD 1,574.38 million by 2034, advancing with stable CAGR of 6.29%.

Top 5 Major Dominant Countries in the Respiratory Humidifiers Segment

• United States: USD 318.20 million in 2025, 35.0% share, forecasted USD 551.03 million by 2034, maintaining consistent CAGR performance of 6.28% throughout forecast period.
• Germany: USD 109.09 million in 2025, 12.0% share, expected USD 188.93 million by 2034, reflecting sustainable CAGR advancement of 6.29% in humidifier adoption.
• China: Valued USD 90.91 million in 2025, 10.0% share, projected USD 157.44 million by 2034, progressing reliably with CAGR of 6.30%.
• Japan: USD 72.73 million in 2025, 8.0% share, forecasted USD 125.95 million by 2034, expanding steadily at CAGR growth of 6.29%.
• India: Estimated USD 54.55 million in 2025, 6.0% share, projected USD 94.46 million by 2034, continuing upward trend with CAGR 6.30%.

Respiratory Oxygen Hoods: Representing 3% of the market, oxygen hoods support over 2.5 million premature infants annually in neonatal intensive care. They remain indispensable for non-invasive respiratory therapy in vulnerable newborns worldwide.

Respiratory Oxygen Hoods market is USD 303.04 million in 2025, representing 1.00% share, projected to grow to USD 524.60 million by 2034, sustaining CAGR expansion of 6.29%.

BY APPLICATION

Hospitals: Hospitals dominate with 37% share. Over 20 million annual critical care admissions globally require ventilators, masks, and resuscitators, reinforcing their role as the largest end-user segment in respiratory device adoption worldwide.

Hospitals segment market is USD 11,010.48 million in 2025, holding 36.35% share, projected to expand to USD 19,056.59 million by 2034, growing steadily at 6.29% CAGR.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: Market size USD 3,853.67 million in 2025, 35.0% share, projected USD 6,670.81 million by 2034, consistently advancing at 6.28% CAGR.
• Germany: Hospitals market USD 1,431.36 million in 2025, 13.0% share, expected USD 2,475.45 million by 2034, reflecting dependable expansion with 6.29% CAGR.
• China: Estimated USD 1,101.05 million in 2025, 10.0% share, forecasted USD 1,905.66 million by 2034, sustaining long-term growth under 6.30% CAGR.
• Japan: Valued USD 880.84 million in 2025, 8.0% share, projected USD 1,524.53 million by 2034, sustaining market trajectory at 6.29% CAGR.
• India: USD 660.63 million in 2025, 6.0% share, expected USD 1,143.40 million by 2034, reflecting consistent hospital adoption with CAGR 6.30%.

Home Care: Home care accounts for 33% demand. Over 10 million patients worldwide rely on oxygen concentrators and CPAP systems for chronic treatment, reflecting shifting preferences toward affordable, convenient, and patient-centered respiratory solutions.

The Home Care segment market is USD 9,394.36 million in 2025, accounting for 31.00% share, expected to expand to USD 16,256.57 million by 2034 with CAGR 6.29%.

Top 5 Major Dominant Countries in the Home Care Application

• United States: Home care valued USD 3,288.03 million in 2025, 35.0% share, forecasted USD 5,689.80 million by 2034, sustaining consistent adoption with CAGR 6.28%.
• Germany: Market estimated USD 1,221.27 million in 2025, 13.0% share, projected USD 2,114.92 million by 2034, reflecting reliable progression within forecast supported by CAGR 6.29%.
• China: Home care segment USD 939.44 million in 2025, 10.0% share, expected USD 1,625.66 million by 2034, expanding consistently at CAGR 6.30%.
• Japan: Estimated USD 751.55 million in 2025, 8.0% share, forecasted USD 1,300.53 million by 2034, reflecting sustainable trajectory with CAGR 6.29%.
• India: Home care size USD 563.66 million in 2025, 6.0% share, projected USD 975.39 million by 2034, steadily rising with CAGR 6.30%.

Other End-Users: Representing 30% share, other end-users include clinics, ambulatory centers, and emergency services. Over eight million respiratory emergencies are managed annually by these facilities, underscoring their important role in device adoption worldwide.

Other End-Users segment market is USD 9,899.55 million in 2025, representing 32.65% share, forecasted to expand to USD 17,146.74 million by 2034, growing consistently under a stable CAGR of 6.29%.

Top 5 Major Dominant Countries in the Other End-Users Application

• United States: Market USD 3,464.84 million in 2025, 35.0% share, projected USD 6,001.36 million by 2034, advancing reliably with steady CAGR 6.28% performance.
• Germany: Other End-Users valued USD 1,286.94 million in 2025, 13.0% share, expected USD 2,229.08 million by 2034, sustaining dependable trajectory with CAGR 6.29%.
• China: Market size USD 989.96 million in 2025, 10.0% share, forecasted USD 1,714.67 million by 2034, maintaining stable adoption at CAGR 6.30%.
• Japan: Other End-Users segment USD 791.96 million in 2025, 8.0% share, projected USD 1,371.74 million by 2034, sustaining consistent CAGR rate 6.29%.
• India: Estimated USD 593.97 million in 2025, 6.0% share, forecasted USD 1,028.80 million by 2034, advancing strongly with dependable CAGR 6.30%.

Respiratory Devices Market Regional Outlook

The Respiratory Devices Market demonstrates varied performance across different regions, shaped by demographics, infrastructure, and disease prevalence.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America holds 41% of the global market share. In the U.S. alone, over 25 million asthma patients and 16 million COPD patients contribute to sustained device demand, making the region a global leader.

North America Respiratory Devices Market is USD 12,424.80 million in 2025, representing 41.00% share, forecasted to reach USD 21,495.56 million by 2034, advancing steadily with a 6.28% CAGR.

North America - Major Dominant Countries in the Respiratory Devices Market

• United States: USD 9,091.32 million in 2025, 73.2% share, projected USD 15,752.20 million by 2034, maintaining steady adoption growth under CAGR rate 6.28%.
• Canada: Market USD 1,366.73 million in 2025, 11.0% share, forecasted USD 2,368.51 million by 2034, progressing consistently under a reliable CAGR growth rate of 6.28%.
• Mexico: Valued USD 932.42 million in 2025, 7.5% share, projected USD 1,615.08 million by 2034, sustaining consistent CAGR expansion trend of 6.28%.
• Cuba: Respiratory devices valued USD 497.00 million in 2025, 4.0% share, expected USD 860.08 million by 2034, sustaining dependable CAGR rate of 6.28%.
• Dominican Republic: Market USD 537.34 million in 2025, 4.3% share, projected USD 929.69 million by 2034, reflecting consistent regional growth supported by CAGR 6.28%.

EUROPE

Europe contributes 27% of global demand, with Germany, France, and the U.K. leading adoption. Over 33 million Europeans suffer from COPD, while 30 million live with asthma, necessitating advanced respiratory support systems.

Europe Respiratory Devices Market is USD 8,182.19 million in 2025, representing 27.00% share, projected to expand to USD 14,154.30 million by 2034, maintaining stable regional trajectory with CAGR of 6.29%.

Europe - Major Dominant Countries in the Respiratory Devices Market

• Germany: Market size USD 2,209.19 million in 2025, 27.0% share, expected USD 3,820.66 million by 2034, sustaining robust expansion under CAGR performance 6.29%.
• France: Valued USD 1,309.15 million in 2025, 16.0% share, forecasted USD 2,263.04 million by 2034, progressing firmly with consistent CAGR rate of 6.29%.
• United Kingdom: Market USD 1,227.33 million in 2025, 15.0% share, projected USD 2,120.88 million by 2034, sustaining reliable adoption across forecast under 6.29% CAGR.
• Italy: Respiratory devices valued USD 981.86 million in 2025, 12.0% share, expected USD 1,696.98 million by 2034, advancing steadily at CAGR rate of 6.29%.
• Spain: Estimated USD 654.58 million in 2025, 8.0% share, forecasted USD 1,131.84 million by 2034, sustaining steady growth supported by CAGR expansion 6.29%.

ASIA-PACIFIC

Asia-Pacific accounts for 29% of the market, fueled by a large patient population. India reports 37 million asthma patients, while China has over 100 million COPD patients, supporting rapid device adoption.

Asia-Pacific Respiratory Devices Market is USD 8,788.27 million in 2025, holding 29.00% share, forecasted to reach USD 15,225.37 million by 2034, sustaining consistent regional momentum under a CAGR of 6.30%.

Asia-Pacific - Major Dominant Countries in the Respiratory Devices Market

• China: Market USD 3,076.89 million in 2025, 35.0% share, projected USD 5,329.88 million by 2034, sustaining reliable expansion with CAGR growth rate of 6.30%.
• India: Respiratory devices valued USD 1,757.65 million in 2025, 20.0% share, forecasted USD 3,046.53 million by 2034, advancing consistently with dependable CAGR trend of 6.30%.
• Japan: USD 1,406.12 million in 2025, 16.0% share, projected USD 2,438.04 million by 2034, maintaining reliable regional adoption under CAGR pace 6.29%.
• South Korea: Market size USD 878.83 million in 2025, 10.0% share, forecasted USD 1,523.15 million by 2034, sustaining strong CAGR momentum of 6.30%.
• Australia: Valued USD 702.62 million in 2025, 8.0% share, projected USD 1,217.92 million by 2034, sustaining dependable expansion under a steady CAGR 6.29%.

MIDDLE EAST & AFRICA

The Middle East & Africa contributes 12% of demand. The region records over 20 million cases of chronic respiratory conditions annually, with South Africa alone reporting 7% adult asthma prevalence.

Middle East and Africa Respiratory Devices Market is USD 2,909.13 million in 2025, accounting for 9.60% share, expected to reach USD 5,080.68 million by 2034, maintaining steady CAGR growth of 6.29%.

Middle East and Africa - Major Dominant Countries in the Respiratory Devices Market

• Saudi Arabia: Market USD 872.74 million in 2025, 30.0% share, projected USD 1,523.14 million by 2034, reflecting dependable regional progression with CAGR 6.29%.
• United Arab Emirates: Valued USD 581.83 million in 2025, 20.0% share, forecasted USD 1,015.91 million by 2034, advancing firmly under a stable CAGR 6.29%.
• South Africa: Market size USD 436.37 million in 2025, 15.0% share, expected USD 761.95 million by 2034, reflecting consistent expansion with 6.29% CAGR.
• Egypt: Respiratory devices USD 290.91 million in 2025, 10.0% share, projected USD 508.07 million by 2034, sustaining consistent growth supported by 6.29% CAGR.
• Nigeria: Estimated USD 218.18 million in 2025, 7.5% share, forecasted USD 381.05 million by 2034, progressing steadily with reliable CAGR trajectory of 6.29%.

List of Top Respiratory Devices Companies

• Invacare Corporation
• Whole You, Inc.
• H&T Presspart Manufacturing Ltd.
• Koninklijke Philips N.V.
• PMD Device Solutions Limited
• Circadiance LLC
• Medtronic PLC
• Chart Industries, Inc.
• Gilbert Technologies BV
• Cipla Inc.
• TotalCare eHealth
• Curative Medical Inc.
• Mylan N.V.
• BMC Medical Co., Ltd.
• Respira Therapeutics, Inc.
• Viroblock Sa
• Adamis Pharmaceuticals Corporation
• 3b Medical, Inc.
• Devilbiss Healthcare LLC
• Pulmatrix Inc.
• Hamilton Medical AG
• Chiesi Farmaceutici S.P.A.
• GE Healthcare
• Vapotherm Inc.
• Teicos Pharma Ltd.
• ResMed Inc.
• Orion Corporation
• Acorda Therapeutics, Inc.
• Omron Healthcare Inc.

Top Two Companies with Highest Market Share:

• Koninklijke Philips N.V.: Philips leads the market with more than 15% share globally, offering a wide portfolio of CPAP systems, ventilators, and oxygen concentrators. In 2023, over 4 million Philips respiratory devices were used worldwide.
• ResMed Inc.: ResMed holds around 12% share, specializing in sleep apnea treatment. Its CPAP devices are used by over 18 million patients globally, making it one of the largest respiratory device suppliers.

Investment Analysis and Opportunities

The Respiratory Devices Market is witnessing significant investment opportunities due to high unmet medical needs, technological innovation, and expanding healthcare infrastructure. Between 2021 and 2024, more than $2.5 billion was invested globally in respiratory device development, with a strong focus on digital health integration and AI-powered monitoring solutions.

Venture capital interest has surged, with over 40% of funding directed toward startups developing wearable and portable respiratory solutions. For example, AI-powered inhalers that track adherence and provide patient data have gained 27% more funding compared to traditional devices.

New Product Development

Innovation is at the heart of the Respiratory Devices Market, with manufacturers focusing on compact, portable, and digitally enabled devices. In 2023, more than 120 new respiratory products were launched globally, with over 40% featuring smart connectivity features.

Portable oxygen concentrators with extended battery life—lasting up to 12 hours—are increasingly preferred, accounting for 55% of new oxygen therapy devices introduced in 2024. CPAP systems with automated air pressure adjustment and real-time compliance tracking have gained traction among sleep apnea patients, increasing treatment adherence rates by 22%.

Five Recent Developments

• In 2023, ResMed launched an AI-enabled CPAP system with real-time patient monitoring, improving therapy adherence by 25%.
• Philips introduced a portable oxygen concentrator in 2024 with a 14-hour battery life, extending mobility for patients.
• In 2024, Medtronic released an advanced ventilator model with automated pressure controls, reducing ICU mortality rates by 18%.
• GE Healthcare announced a digital respiratory monitoring system in 2025, integrating patient data into hospital EHR systems.
• Vapotherm launched a high-flow nasal cannula device in 2025, capable of delivering up to 60 liters per minute oxygen flow.

Report Coverage of Respiratory Devices Market

The Respiratory Devices Market Report provides comprehensive insights into global demand, regional outlook, segmentation, and competitive dynamics. Covering data from 2018 through 2025, the report emphasizes the role of technological advancements, demographic shifts, and disease prevalence in shaping market performance.

The report evaluates respiratory devices across multiple categories, including ventilators, inhalers, CPAP devices, nebulizers, oxygen concentrators, humidifiers, and masks. It assesses adoption across end-user segments such as hospitals, home care, and other healthcare facilities, providing a detailed perspective on consumption patterns.

Respiratory Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 32210.54 Million in 2026
Market Size Value By	USD 55759.64 Million by 2035
Growth Rate	CAGR of 6.29% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Respiratory Positive Airway Pressure Devices Respiratory Mask Respiratory Ventilators Respiratory Oxygen Concentrators Respiratory Inhalers Respiratory Resuscitators Respiratory Nebulizers Respiratory Humidifiers Respiratory Oxygen Hoods By Application : Hospitals Home Care Other End-Users
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample